2017-2020年美国商业与Medicare理赔数据库中成人血栓伴血小板减少综合征(TTS)发病率
基于美国多个商业与Medicare理赔数据库,估算2017-2020年成人总体TTS、常见部位TTS及罕见部位TTS的年度与月度发病率。总体TTS年发病率2019年与2020年相似,Medicare高于商业数据库,常见部位TTS随年龄增长且男性更高,罕见部位TTS在商业数据中男性更高且随年龄增长。
要点
- 总体TTS年发病率2019年与2020年相似,Medicare高于商业数据库。
- 常见部位TTS发病率随年龄增长,且男性高于女性。
- 罕见部位TTS在商业数据中男性更高且随年龄增长,Medicare中≥65岁随年龄下降。
核心结论
- TTS发病率各年总体相似,男性更高,且随年龄增长;这些率可用于新冠疫苗接种后TTS监测的背景参考。
研究设计与样本
- 利用Carelon Research与MarketScan商业理赔(2017年-2020年10月)、CVS Health与Optum商业理赔(2019年-2020年10月)估算18-64岁成人TTS发病率,利用CMS Medicare理赔(2019年-2020年10月)估算≥65岁成人TTS发病率,并按年龄、性别、种族/族裔(CMS Medicare)分层。
主要发现
- 总体TTS年发病率在2019年1-12月与2020年1-10月相似:Medicare 2019年370.72/10万人年、2020年365.63/10万人年;MarketScan 24.21与24.06;Optum 32.60与31.29;Carelon Research 24.46与26.16;CVS Health 30.31与30.25。
- 常见部位TTS发病率在各年和数据库均随年龄增长,且男性高于女性。
- ≥65岁成人中,常见部位TTS发病率在非西班牙裔黑人成人中最高。
- 罕见部位TTS年发病率2019年1-12月商业数据库为2.02-3.04/10万人年、Medicare为12.49/10万人年;2020年1-10月商业数据库为1.53-2.67/10万人年、Medicare为11.57/10万人年。
- 商业数据中罕见部位TTS发病率男性更高且随年龄增长;≥65岁成人中发病率随年龄下降,非西班牙裔美国印第安/阿拉斯加原住民成人中最高。
关键数值与推荐
- 总体TTS年发病率(每10万人年):Medicare 2019年370.72、2020年365.63;MarketScan 2019年24.21、2020年24.06;Optum 2019年32.60、2020年31.29;Carelon Research 2019年24.46、2020年26.16;CVS Health 2019年30.31、2020年30.25。
- 罕见部位TTS年发病率(每10万人年):2019年1-12月商业数据库2.02-3.04、Medicare 12.49;2020年1-10月商业数据库1.53-2.67、Medicare 11.57。
临床怎么用
- 这些发病率可为新冠疫苗接种后TTS被动监测报告提供背景参考。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Increased risk of thrombosis with thrombocytopenia syndrome (TTS) following adenovirus vector-based COVID-19 vaccinations has been identified in passive surveillance systems. TTS incidence rates (IRs) in the United States (U.S.) are needed to contextualize reports following COVID-19 vaccination. METHODS: We estimated annual and monthly IRs of overall TTS, common site TTS, and unusual site TTS for adults aged 18-64 years in Carelon Research and MarketScan commercial claims (2017-Oct 2020), CVS Health and Optum commercial claims (2019-Oct 2020), and adults aged ≥ 65 years using CMS Medicare claims (2019-Oct 2020); IRs were stratified by age, sex, and race/ethnicity (CMS Medicare). RESULTS: Across data sources, annual IRs for overall TTS were similar between Jan-Dec 2019 and Jan-Oct 2020. Rates were higher in Medicare (IRs: 370.72 and 365.63 per 100,000 person-years for 2019 and 2020, respectively) than commercial data sources (MarketScan IRs: 24.21 and 24.06 per 100,000 person-years; Optum IRs: 32.60 and 31.29 per 100,000 person-years; Carelon Research IRs: 24.46 and 26.16 per 100,000 person-years; CVS Health IRs: 30.31 and 30.25 per 100,000 person-years). Across years and databases, common site TTS IRs increased with age and were higher among males. Among adults aged ≥ 65 years, the common site TTS IR was highest among non-Hispanic black adults. Annual unusual site TTS IRs ranged between 2.02 and 3.04 (commercial) and 12.49 (Medicare) per 100,000 person-years for Jan-Dec 2019; IRs ranged between 1.53 and 2.67 (commercial) and 11.57 (Medicare) per 100,000 person-years for Jan-Oct 2020. Unusual site TTS IRs were higher in males and increased with age in commercial data sources; among adults aged ≥ 65 years, IRs decreased with age and were highest among non-Hispanic American Indian/Alaska native adults. CONCLUSION: TTS IRs were generally similar across years, higher for males, and increased with age. These rates may contribute to surveillance of post-vaccination TTS.
引用
- Lloyd PC, Lufkin B, Moll K, et al. Incidence rates of thrombosis with thrombocytopenia syndrome (TTS) among adults in United States commercial and Medicare claims databases, 2017-2020. Vaccine. 2024. PMID: 38388240. doi:10.1016/j.vaccine.2024.02.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。